Related Experiment Video
Updated: Aug 16, 2026
Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
Published on: August 6, 2014
mdm-2 expression in human testicular germ-cell tumors and its clinical value
1Department of Cytopathology, National Institute of Oncology, Budapest, Hungary.
Background:
In germ cell testicular tumors (GCTT) mdm-2 gene was analyzed for amplification and transcripts but not for protein. The purpose of this study is to determine whether mdm-2 protein level is aberrant in GCTT and if so, what is the relationship between mdm-2 overexpression and other disease parameters including histologic subtypes, p53 status, metastatic potential and clinical stage.
Methods:
81 testicular germ-cell tumors were screened for their mdm-2 expression at the protein levels using immunohistochemistry (IHC) and Western blot (WB) analysis.
Results:
Of 81 GCTTs 45 (55.55%) showed mdm-2 nuclear immunoreactivity, 34 (41.97%) of which were strongly positive. The incidence of mdm-2 immunostaining was significantly higher (P = 0.0007) in non-seminomas (NSGCT) than in seminomas (SGCT). The frequency of positive tumor was higher in tumors from metastatic patients than in tumors from metastatic-free patients (P = 0.011). mdm-2 expression was detected significantly more frequently in tumors of advanced stages, i.e. IIB, IIC and III versus tumors of early stages (I and II/A) (P = 0.0098). A significant difference between the three stages of disease as to the expression of mdm-2 (chi 2 = 0.0386) could be established, namely the incidence of mdm-2 expression increased with an increase in stage. Using Westem blotting 22 (68.75%) out of 32 tumors overexpressed the mdm-2 oncoprotein of 90 kd (p90).
Conclusions:
mdm-2 expression as detected by immunohistochemistry may provide a reliable prognostic tool to isolate subgroups of patients with more aggressive GCTT.
Insights
MDM-2 protein overexpression is common in germ cell testicular tumors (GCTT), particularly in non-seminomas and advanced stages. This finding suggests MDM-2 protein levels can help identify aggressive GCTT for better patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Germ cell testicular tumors (GCTT) are a significant health concern.
- Previous studies analyzed the mdm-2 gene but not its protein product in GCTT.
- The role of mdm-2 protein in GCTT pathogenesis remains unclear.
Purpose of the Study:
- To investigate mdm-2 protein expression levels in GCTT.
- To determine the correlation between mdm-2 overexpression and clinicopathological features of GCTT, including histologic subtypes, p53 status, metastatic potential, and clinical stage.
Main Methods:
- Immunohistochemistry (IHC) and Western blot (WB) analyses were employed.
- 81 testicular germ-cell tumors were assessed for mdm-2 protein expression.
- Expression levels were correlated with clinical and pathological data.
Main Results:
- MDM-2 nuclear immunoreactivity was observed in 55.55% of GCTTs, with 41.97% showing strong positivity.
- MDM-2 expression was significantly higher in non-seminomas (NSGCT) than in seminomas (SGCT) (P = 0.0007).
- Increased mdm-2 expression correlated with metastatic status (P = 0.011) and advanced clinical stages (P = 0.0098).
- Western blot analysis confirmed mdm-2 oncoprotein overexpression in 68.75% of analyzed tumors.
Conclusions:
- MDM-2 protein overexpression is a frequent event in GCTT.
- Immunohistochemical detection of mdm-2 expression can serve as a prognostic marker.
- This marker may aid in identifying patient subgroups with more aggressive GCTT, guiding treatment decisions.
